Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 4/20 | 0.32 |
| ▸ | PLK1 | P53350 | 2/20 | 0.31 |
| ▸ | CFTR | P13569 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.31 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.30 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.30 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611164 | 0.91 | EGFR (0.33) | EGFRBTKCFTR | |
| SCHEMBL16611078 | 0.87 | SCN9A (0.34) | EGFRPLK1CFTR | |
| SCHEMBL16610768 | 0.77 | POLB (0.35) | — | |
| SCHEMBL16611035 | 0.72 | BTK (0.42) | BTK | |
| SCHEMBL16611538 | 0.71 | MERTK (0.34) | EGFRBTKOPRK1 | |
| SCHEMBL16610812 | 0.69 | — | — | |
| SCHEMBL16611289 | 0.64 | CSNK2A1 (0.35) | EGFRBTK | |
| SCHEMBL20077994 | 0.63 | CTPS1 (0.37) | — | |
| SCHEMBL25174515 | 0.62 | BTK (0.41) | BTK | |
| SCHEMBL16611927 | 0.62 | CFTR (0.32) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | EGFR 4532/4885BTK 117/4885PLK1 85/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | EGFR 4532/4885BTK 117/4885PLK1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.